APRIL 2018

Nurturing Shareholder GrowthEMBLEM CORP. | TSXV: EMC

DISCLAIMER

This documentation is a presentation (the “Presentation”) of general background information about Emblem Corp’s., (“Emblem”) activities current as of April 15, 2018. It is information in a summary formand does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs ofany particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate.

The information contained in this Presentation is derived solely from management of Emblem and otherwise publicly available third party information and does not purport to be all-inclusive or to containall the information that an investor may desire to have in evaluating whether or not to make an investment in Emblem. The third party information has not been independently verified. No representation orwarranty, express or implied, is made or given by or on behalf of Emblem or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinionscontained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. Emblem does not undertake or agree to update this Presentation after the datehereof. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representationsmust not be relied upon as having been so authorized. The information and opinions contained in this Presentation are provided as at the date of this Presentation. The contents of this Presentation are notto be construed as legal, financial or tax advice.

Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice. Certain statements in this Presentation may constituteforward-looking information, including future-oriented financial information and financial outlooks, within the meaning of applicable securities laws. Forward looking information may relate to Emblem’sfuture outlook and anticipated events or results and may include statements regarding Emblem’s financial results, future financial position, expected growth of cash flows, business strategy, budgets,projected costs, projected capital expenditures, taxes, plans, objectives, potential synergies, industry trends, construction schedules, construction budgets, and growth opportunities.

Often but not always, forward-looking information can be identified by the use of words such as “anticipate”, “believe”, “expect”, “project”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “might”,“target”, “plan” and other similar expressions or variations (including negative variations) of such words and phrases. Forward-looking information contained in this Presentation is based on certainassumptions regarding expected growth, results of operations, performance, industry trends and growth opportunities. While management considers these assumptions to be reasonable, based oninformation available, they may prove to be incorrect. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance orachievements of Emblem to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and otherfactors include, but are not limited to risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involvingmedical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canadagenerally, income tax and regulatory matters; the ability of Emblem to implement its business strategies; including facility, expansion, within budget and on the schedule currently anticipated; competition;crop failure; currency and interest rate fluctuations, and the other risks common for a business such as Emblem’s. The foregoing factors are not intended to be exhaustive.

Although Emblem has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be otherfactors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date hereof and Emblem and its directors,officers and employees disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance thatforward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue relianceon forward-looking statements due to the inherent uncertainty therein. All forward-looking information is expressly qualified in its entirety by this cautionary statement. Forward-looking information andother information contained herein concerning management’s general expectations concerning the medical marijuana industry are based on estimates prepared by management using data from publiclyavailable industry sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which management believes to be reasonable. However,this data is inherently imprecise, although generally indicative of relative market positions, market shares and performance characteristics. While management is not aware of any misstatements regardingany industry data presented herein, industry data is subject to change based on various factors.

This Presentation may not be reproduced, further distributed or published in whole or in part by any other person. Neither this Presentation nor any copy of it may be taken or transmitted into or distributedin any other jurisdiction which prohibits the same except in compliance with applicable laws. Any failure to comply with this restriction may constitute a violation of applicable securities law. Recipients arerequired to inform themselves of, and comply with, all such restrictions or prohibitions and Emblem does not accept liability to any person in relation thereto.

INTRODUCING

FOCUSED ON GROWING SHAREHOLDER VALUE,NOT JUST GROWING CANNABIS.

HOW:LEVERAGING OUR PROFESSIONAL STRENGTHS TO DOMINATE IN THE HIGHLY PROFITABLE, VALUE-ADD SPACE.

OUR WINNING FORMULA:PRODUCT INNOVATION + BRAND RELEVANCE + ACCESS TO PATIENT/CONSUMER.

EMBLEM AT A GLANCE

TICKER SYMBOL TSXV:EMC

FOUNDED 2013

RECENT SHARE PRICE (APRIL 13, 2018) C$1 .54

SHARES ISSUED & OUTSTANDING (BASIC)1 1 19 ,060 ,512

C$183 MILL IONMARKET CAPITALIZATION (BASIC)1

SHARES ISSUED & OUTSTANDING (DILUTED)1 187 ,239 ,416

CURRENT PATIENT COUNT ~3 , 100

PRODUCTION FACILITY PARIS , ONTARIO (~65 EMPLOYEES)

CURRENT PRODUCTION CAPACITY ~2 ,000 KG

Q1 2019 PRODUCTION CAPACITY TARGET ~17 ,000 KG

TOTAL CASH POSITION ~$85 MILL ION

CASH PROCEEDS (FROM ALL OUTSTANDING WARRANTS AND OPTIONS)1 ~$107 MILL ION

INSIDER OWNERSHIP (BASIC)1 ~20%

1As of April 13, 2018

BUILDING A ‘REAL’ BUSINESS BASED ON FUNDAMENTALS

3 KEY OPERATING UNITS

EMBLEM CORP.

MEDICAL

PATIENT ACQUISITION/PRODUCT INNOVATION

ADULT-USE

CULTIVATION

HOUSE OF BRANDS/ACCESS TO CONSUMER

UNIQUE STRAINS/CONNECTED CULTIVATION

PRESIDENT & CEO

EMBLEM LEADERSHIP TEAM

CHIEF FINANCIAL OFFICER

NICK DEAN

ALEX STOJANOVIC

FOUNDER, INT’L DEVELOPMENTMAXIM ZAVET

PRESIDENT, EMBLEM MEDICALJOHN STEWART

COO, EMBLEM MEDICAL

CHIEF MARKETING OFFICER

ADAM SAPERIA

MARIA GUEST

GENERAL MANAGER, OPERATIONSJEFF KEYES

FUTURE GROWTH DRIVERS

MEDICAL

NEW PRODUCTS

INTERNATIONAL

RECREATIONAL

Can

nabi

s In

dust

ry

Cultivation

Processing & Formulation

Product Innovation

House of Brands

Marketing & Exposure

Distribution

THE FUTURE:Higher-margin, value-add product

Creating product demand through a strategic, targeted and focused approach to patient/customer

acquisition

THE PAST:Commoditization, over supply & lower margins

THE FUTURE OF CANNABIS

PROCESSING & FORMULATION

Fully-funded 30,000 sq. ft. state-of-the-art integrated building that includes a 5,000 sq. ft. formulation and analytical laboratory

Expected to be completed & licensed by Q3 2018

Run by John Stewart, world-renowned pharma executive

Built to GMP certification, allowing for future export market potential

FOCUS WILL BE ON:

Production of oils

Development of novel formulations for all market segments

Working with partners to develop best-in-class products demanded by the market

PREMIUMFLOWERPROPRIETARY GENETICS

• Quantum Kush – THC: 23-26%• Dela Haze – THC: 13-14%• MK Ultra – THC: 16%• Black Widow – THC: 5.3-6.9%, CBD: 8.8-10.9%• High Voltage – THC: 0.4%, CBD: 12.5-18%

PRODUCT STRATEGY

4 OILSLAUNCHEDDECEMBER 2017

SIGNIF ICANT POSIT IVE IMPACTTO SALES S INCE LAUNCH.

PRODUCTION CAPACITY : 5 ,000/MONTH

PRODUCT STRATEGY

OIL-F ILLEDCANNABIS CAPSULESLAUNCHING Q3 2018*

EMBLEM WILL MANUFACTURE AND PACKAGE IN-HOUSE , OFFERING ALL FOUR OF THE COMPANY’S CANNABIS OILS IN CAPSULES :AT 2 .5 , 5 .0 AND 10 .0 MG STRENGTHS

NOVEL FORMULATION DEVELOPMENTIN-HOUSE

PRODUCT STRATEGY

*Pending Health Canada approval.

DOSECANNLICENSING AGREEMENT

CANNABIS-OIL ORAL SPRAY DOSAGE FORM LAUNCHING Q3*

*Pending Health Canada approval.

NOVEL FORMULATION DEVELOPMENTPARTNERSHIP

PRODUCT STRATEGY

EXCLUSIVE AGREEMENT TO PRODUCE CANNABINOID BASED ORAL SUSTAINED RELEASE FORMULATION.LAUNCHING 2019*

Under the Agreement, Emblem and Canntab will collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of the Sustained Release Product.

The Agreement grants to Emblem the exclusive right in Canada to Canntab’s patents and know-how for the purpose of developing, commercializing, using, selling, and offering the Sustained Release Product for sale under the Emblem brand.

*Pending Health Canada approval.

NOVEL FORMULATION DEVELOPMENTPARTNERSHIP

PRODUCT STRATEGY

SETT ING THESTANDARDFOR PRODUCTINNOVATION

FUTURE PRODUCT STRATEGY

*Pending Health Canada approval.

Product quality and brand strength will dominate the hearts and minds of consumers and end-users. Emblem will be a leader in bringing World-class product innovation to market in 2019.*

BEVERAGES EDIBLES VAPE PENS

TOPICALS CONCENTRATES

HOUSE OF BRANDS

MEDICAL

ADULT USE

BESTBETTER

BRAND TBABRAND TBA

DIRECT TO PATIENT :

Continue to sell through current channel, building patient base by utilizing

Shoppers Drug Mart (when available)

MEDICAL ADULT-USE

BRAND CENTRIC :

OCS

AGLC

Fire & Flower (other dispensaries)

Focus on ‘educating’ the distribution points to ensure they arerecommending our products

GMP CERTIF ICATION

GERMANY JOINT VENTURE

INTERNATIONAL

DISTRIBUTION

PATIENT ACQUISITION STRATEGY

GROWWISEGrowWise Health is a cannabis education company that provides a healthcare solution for physicians and patients currently lacking in the Canadian medical cannabis industry.

GROWWISE EDUCATION CENTRESFILLING THE ROLE OF THE PHARMACIST

• GrowWise operates in medical clinics in which doctors are prescribing cannabis

• Patients are referred to GrowWise once a prescription has been issued

• Nurses counsel patients on safety, strain selection, and assist patients with registering, and placing orders with a licensed producer

• GrowWise is a reliable and consistent source of patients for Emblem

CULTIVATION - CLOSED BOX STRATEGY

THE FACIL ITY | PHASE 1+2

FULLY FUNDED

WOODSLEE

FULLY FUNDED

CLOSED BOX / GMP CERTIFIED LAB

LOW COST, PREMIUM QUALITY FLOWER

2,000 KGS/ANNUM

COMPLETION Q3 2018

CULTIVATION - GREENHOUSE STRATEGY

PARIS ROAD

80 ACRES COMMERCIAL LAND

PHASE 1 : ~170K SQ.FT PURPOSE-BUILT GREENHOUSE

15,000 KGS – HIGHER VOLUME, LOWER COST

FULLY FUNDED

RAW MATERIAL FOR EXTRACTS & VALUE-ADD

ONLINE Q1 2019

FUNDAMENTAL STRATEGY

OUR CONNECTED ECOSYSTEM

DISTRIBUTIONUtilizing strategic relationships to

have products available across domestic and international

distribution channels.

PRODUCTSDevelop best in class products

designed to meet consumer needs and wants through all sales channels.

CULTIVATIONUtilizing Woodslee facility for high quality dried flower and Paris Road

for oil processing.

BRANDING& MARKETING

Identifiable brands across medical, health & wellness and recreational to

build customer loyalty.

PROCESSING& FORMULATION

Highest quality, consistent and unique formulations through our

30,000 sq ft lab.

We’re Emblem and thisis just the beginning.Thank you.